Ashurst advised STADA Arzneimittel AG ("STADA") on the successful issuance of a €300 million corporate bond. The bond was subscribed by an international banking consortium comprising Commerzbank, DZ BANK AG, HSBC and UniCredit and was placed with institutional as well as private investors in more than ten countries. The seven-year bond has an annual interest rate of eight per cent. and was admitted to trading on the Luxembourg Stock Exchange.

The Ashurst team was led by Frankfurt-based debt capital markets partner Dr Tobias Krug, assisted by associates Dr Angela Loff (equity capital markets) and Alexandra Heitmann (debt capital markets).

STADA is a listed pharmaceutical company based in Bad Vilbel, Germany which consistently focuses on a multi-pillar-strategy of generic and over-the-counter drugs whilst increasingly orienting towards the global market.

Ashurst's German debt capital markets practice advises both issuers and investment banks in connection with national and international capital market transactions, in particular regarding straight bonds, bonds with warrants and convertible bonds, structured notes and derivatives as well as regarding the drafting of template programmes for the issuance of German Schuldschein loans and registered bonds and on the related regulatory matters.